Last edition
News about "Notice of Compliance (NOC)"
LYNKUET (Elinzanetant) Gets Expanded Canada Approval for Breast Cancer-Related Hot Flashes
LYNKUET (elinzanetant) receives expanded Canadian authorisation to treat moderate to severe hot flashes and night sweats caused by breast cancer Adjuvant Endocrine Therapy (AET).
Notice Of Compliance (NOC) | 18/08/2026 | By News Bureau | 178
Dr. Reddy's Launches Generic Semaglutide Injection in Canada
Dr. Reddy's Laboratories launches Canada’s first approved generic semaglutide injection after receiving Health Canada clearance, marking the first G7 market authorisation.
Notice Of Compliance (NOC) | 16/05/2026 | By News Bureau | 272
Dr. Reddy's Laboratories Wins Health Canada Nod for Generic Semaglutide Injection
Dr. Reddy's Laboratories secures Health Canada approval for generic semaglutide injection, becoming the first to gain market authorisation in Canada ahead of the review timeline.
Notice Of Compliance (NOC) | 29/04/2026 | By News Bureau | 196
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy